Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
Volume 1.58M
Average 1.61M
AVTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Avalo Therapeutics, Inc.NASDAQ: AVTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $14.05M rose 54.0% year over year, behind the +74.4% change in trailing-twelve-month research & development. Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.
Context
- Research & development amounted to 84888.1% of revenue in FY2025, up 73079.1 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +54.0% toward the trailing-twelve-month pace of +74.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 50.08M USD
- Year-over-year change
- -3.8%
- 4-year CAGR
- -4.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.08M | -3.8% |
| FY2024 | 2024-12-31 | 52.08M | +277.8% |
| FY2023 | 2023-12-31 | 13.78M | -56.0% |
| FY2022 | 2022-12-31 | 31.31M | -47.7% |
| FY2021 | 2021-12-31 | 59.84M | — |
Research & Development vs competitors
How AVTX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +74.4% is the highest of 10, against a peer median of +11.4%.
- Research & development amounts to 93235.6% of revenue for AVTX, versus a peer median of 265.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $259.72M USD | +46.3% | +43.1% | 287.0% | |
| LTM Jun 2026 | $255.77M USD | +11.4% | +6.3% | 243.6% | |
| LTM Mar 2026 | $128.65M USD | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $86.08M USD | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $69.93M USD | +20.4% | +34.8% | — | |
| LTM Mar 2026 | $56.72M USD | +60.6% | -12.2% | 677.9% | |
| LTM Mar 2026 | $55.01M USD | +74.4% | +17.0% | 93235.6% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €39.31M EUR | +49.4% | — | — |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $15.25M USD | -66.4% | -18.8% | 28.4% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AVTX) | — | +11.4% | +5.5% | 265.3% | |
Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.4M | 18.05M | 1.92M | 441K | 59K |
| Cost of Revenue | 1.49M | 3.43M | 1.28M | (366K) | 0 |
| Gross Profit | 3.91M | 14.62M | 640K | 807K | 59K |
| Gross Margin | 72.4% | 81.0% | 33.3% | 183.0% | 100.0% |
| Research & Development | 59.84M | 31.31M | 13.78M | 52.08M | 50.08M |
| Selling, General & Admin | 24.66M | 20.71M | 10.3M | 17.24M | 22.9M |
| Operating Expenses | 86.04M | 52.06M | 27.99M | 69.32M | 72.98M |
| Depreciation & Amortization | 1.66M | 166K | 158K | 169K | 344K |
| EBITDA | (80.5M) | (37.29M) | (23.29M) | (34.85M) | (77.75M) |
| EBITDA Margin | -1491.2% | -206.6% | -1210.3% | -7901.6% | -131779.7% |
| Operating Income | (82.13M) | (37.44M) | (27.35M) | (68.51M) | (72.93M) |
| Operating Margin | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| Interest Income | 0 | 0 | 0 | 3.32M | 4.35M |
| Interest Expense | 2.39M | 4.17M | 3.42M | 0 | 0 |
| Other Income / Expenses | (2.41M) | (4.19M) | (4.18M) | 33.5M | (5.17M) |
| Income Before Tax | (84.55M) | (41.63M) | (31.53M) | (35.02M) | (78.09M) |
| Pre-Tax Margin | -1566.2% | -230.6% | -1638.8% | -7939.9% | -132362.7% |
| Income Tax Expense | (196K) | 28K | 14K | 114K | 165K |
| Net Income | (84.38M) | (41.66M) | (31.54M) | (35.13M) | (78.26M) |
| Net Margin | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
| EPS (Basic) | (2,330.66) | (1,062.65) | (113.58) | (4.32) | (5.84) |
| EPS (Diluted) | (2,330.66) | (1,062.65) | (113.58) | (3.26) | (5.84) |
| Weighted Avg Shares | 36.19K | 39.2K | 277.73K | 8.13M | 13.4M |
| Weighted Avg Shares (Diluted) | 36.19K | 39.2K | 277.73K | 10.78M | 13.4M |
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.